跳至主要内容
临床试验/NCT04654455
NCT04654455已完成不适用

Prospective Study Evaluating Dry Eye in Patients Operated on for Ametropia by LASIK Surgery and Treated With REPADROP

Hospices Civils de Lyon1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2021年3月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10
试验地点
1
主要终点
Variation in OSDI (Ocular Surface Disease Index) score

研究概览

简要总结

LASIK is a refractive surgery technique widely used in France. Postoperatively, the classic treatment after LASIK consists of instilling drops to reduce dry eyes. REPADROP® is an innovative eye drops stimulating corneal innervation. To date no study has quantified the improvement in dry eye syndrome and thus the quality of life of patients using REPADROP®.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age over 18
  • Planned bilateral LASIK surgery
  • Use of Repadrop as postoperative eye drops
  • Patient agreement to participate

排除标准

  • History of corneal pathology
  • History of treatment with REPADROP® or CACICOL® or NGF® (other eye drops which are no longer available on the market to date but which would also improve corneal healing)
  • Ongoing treatment with topical cyclosporine
  • Presence of punctal plugs
  • Adults who are the subject of a legal protection measure (guardianship, curators)
  • Pregnant or breastfeeding women

结局指标

主要结局

Variation in OSDI (Ocular Surface Disease Index) score

时间窗: 3 Months

Variation in OSDI (Ocular Surface Disease Index) score between 1 month and 3 months post-LASIK. The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验